Skip to main content

2019

November 22, 2019
Background: Tardive dyskinesia (TD) is a debilitating, often-irreversible hyperkinetic movement disorder that impairs patients’ abilities to perform daily activities. Deutetrabenazine was FDA-…
November 22, 2019
Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I disorder…
November 22, 2019
Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY trial…
November 22, 2019
OBJECTIVE: This survey intends to fill a research and educational gap by conducting an in-depth anonymous online survey of U.S. adults, investigating the impact of past psychedelic use and the impact…
November 22, 2019
Background: Literature showed that depression was strongly associated with poor oral health including dental caries and periodontitis. The aim of this study was to examine the association between…
November 22, 2019
Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-deficit/…
November 22, 2019
Introduction: Abrupt discontinuation of opioids after chronic use can result in severe, distressing symptoms that result from central noradrenergic hyperactivity. Avoidance of opioid withdrawal…
November 22, 2019
Objective: The aim of the current study was to evaluate the long-term safety and effectiveness of lurasidone in pediatric bipolar depression. Method: Patients 10-17 years with bipolar I depression…
November 22, 2019
Background: Medication adherence is critical for relapse prevention among SMI patients. In the absence of objectively collected adherence data (OCAD), managing medications is difficult. A digital…
November 22, 2019
Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into the evening…
Back to Top